Skip to main content

Advertisement

SpringerLink
Log in

Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France

  • Concise Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The aim of the study presented here was to evaluate the in vitro activity of faropenem, a new member of the penem class intended for oral administration, compared with 11 other antimicrobial agents against a large number of Streptococcus pneumoniae strains isolated from adults and children with bloodstream infections in France. The minimum inhibitory concentration of faropenem against 90% of the pediatric strains tested was generally one to two dilutions lower than the most potent beta-lactam agents (i.e., 0.5 µg/ml for faropenem vs. 1 for amoxicillin, 1 for cefotaxime and 0.5 µg/ml for ceftriaxone). Against the adult strains, only moxifloxacin had a MIC90 value similar to faropenem (i.e., 0.25 µg/ml for both agents). Faropenem seems to be a promising antimicrobial agent for the treatment of adult and pediatric Streptococcus pneumoniae infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Wishwa NK (1996) Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275:134–141

    Article  CAS  PubMed  Google Scholar 

  2. Kalin M, Ortqvist A, Almela M, Aufwerber E, Dwyer R, Henriques B, Jorup C, Julander I, Marrie TJ, Mufson MA, Riquelme R, Thalme A, Torres A, Woodhead MA (2000) Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 182:840–847

    Article  CAS  PubMed  Google Scholar 

  3. Kaplan SL, Mason EO Jr (1998) Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 11:628–644

    CAS  PubMed  Google Scholar 

  4. Spangler SK, Jacobs MR, Appelbaum PC (1994) In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 38:2902–2904

    CAS  PubMed  Google Scholar 

  5. Reinert RR, Lutticken R, Lemperle M, Bryskier A (1999) A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 43 (Suppl C):5–8

    Article  CAS  Google Scholar 

  6. Comité de l'Antibiogramme de la Société française de Microbiologie. (2002) Communiqué 2002.http://www.sfm.asso.fr/Sect4/com2002.pdf

  7. Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF (2003) Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000–2001: a comparison with other beta-lactam agents. J Antimicrob Chemother 51:196–199

    Article  CAS  PubMed  Google Scholar 

  8. Von Eiff C, Becker K, Machka K, Stammer H, Peters G (2001) Nasal carriage as a source of Staphylococcus aureus bacteraemia. N Engl J Med 344:11–16

    Article  PubMed  Google Scholar 

  9. Adam D (2002) Global antibiotic resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50 (Suppl):1–5

    CAS  Google Scholar 

  10. European Antimicrobial Resistance Surveillance System. Database (2002)http://www.earss.rivm.nl/PAGINA/interwebsite/home_earss.html

  11. Felmingham D, Gruneberg RN (2000) The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 45:191–203

    Article  CAS  PubMed  Google Scholar 

  12. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, Reiss PT, Medeiros AA (2002) Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 35:556–564

    Article  CAS  PubMed  Google Scholar 

  13. Waterer GW, Wunderink RG, Jones CB (2000) Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 118:1839–1840

    Article  CAS  Google Scholar 

  14. Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE (1999) Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 29:321–327

    CAS  PubMed  Google Scholar 

  15. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF (2000) Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 30:520–528

    Article  CAS  PubMed  Google Scholar 

  16. Woodcock JM, Andrews JM, Brenwald NP, Ashby JP, Wise R (1997) The in-vitro activity of faropenem, a novel oral penem. J Antimicrob Chemother 39:35–43

    Article  CAS  Google Scholar 

  17. Du Plessis M, Capper TP, Klugman KP (2002) In vitro activity of faropenem against respiratory pathogens. J Antimicrob Chemother 49:575–577

    Article  PubMed  Google Scholar 

  18. Marchese A, Debbia EA, Bryskier A, Schito GC (1999) Antimicrobial activity of faropenem, a new oral penem, against lower respiratory tract pathogens. Clin Microbiol Infect 5:282–287

    CAS  PubMed  Google Scholar 

  19. Schmitz FJ, Boos M, Mayer S, Verhoef J, Milatovic D, Fluit AC (2001) In vitro activity of faropenem and 21 other compounds against 385 different genetically characterized isolates of antibiotic-resistant Streptococcus pneumoniae. J Antimicrob Chemother 48:148–152

    Article  CAS  PubMed  Google Scholar 

  20. Gress TW, Yingling KW, Stanek RJ, Mufson MA (1996) Infection with Streptococcus pneumoniae moderately resistant to penicillin does not alter clinical outcome. Infect Dis Clin Prac 5:435–439

    Google Scholar 

  21. Gemmell CG (2001) Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 48:47–52

    Article  CAS  PubMed  Google Scholar 

  22. Maugein J, Guillemot D, Dupont MJ, Fosse T, Laurans G, Roussel-Delvallez M, Thierry J, Vergnaud M, Weber M, Poirier B (2003) Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in eight French counties. Clin Microbiol Infect 9:280–288

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the following laboratories for providing clinical isolates for use in the study: Pediatric Streptococcus pneumoniae strains: A. Collignon (Centre Hospitalo-Universitaire Jean Verdier, Bondy), C. Chaplain (Centre Hospitalier, Saint Denis), A. Fremaux and E. Estrangin (Centre Hospitalier Intercommunal, Créteil), J.-C. Ghnassia (Hôpital A. Mignot, Versailles); Adult Streptococcus pneumoniae strains: A. Mandjee (Centre Hospitalier, Romans), M. Marcolin (Centre Hospitalier d'Arras), M. Morillon (Hôpital des Armées Laveran, Marseille), G. Otterbein (Hôpital Sainte Camille, Bry sur Marne), B. Pangon (Hôpital A. Mignot, Versailles), J.G. Paul (Centre Hospitalier Duchenne, Boulogne sur Mer), N. Peyrard (Centre Hospitalier, Beaune), D. Pierrejean (Centre Hospitalier, Auch), P. Pouedras (C.H.P. Chubert Vannes), G. Rast (Centre Hospitalier Intercommunal, Poissy), J.C. Reveil and C. Auvray (Centre Hospitalier, Charleville Mezieres), P. Roos (Hôpital Bel Air, Thionville), O. Sabot (Centre Hospitalier, Belley), S. Samaille (Centre Hospitalier, Saint Omer), R. Sanchez (Centre Hospitalier, Perigueux), A. Secher (Centre Hospitalier, Chartres), H. Senechal (Centre Hospitalier, Quimperle), H. Sep-Hieng (Centre Hospitalier, Avranches), D.-P. Simeon (Centre Hospitalier, Langres), A. Vachée (Centre Hospitalier, Roubaix), E. Vallée (Centre Hospitalier, Eaubonne), J. Vaucel (Centre Hospitalier la Beauchée, Saint-Brieuc), M. Villemain (Centre Hospitalier, Aurillac), C. Cattoen (Centre Hospitalier Général, Valenciennes), A.-M. Astoul (Centre Hospitalier Général, Brive La Gaillarde), J. Texier-Maugin (Hôpital Haut Lévèque, Pessac), G. Aubert (Hôpital Bellevue, Saint-Etienne), J. Cottin (Hôpital Hôtel Dieu, Angers), A. Le Faou (Hôpital d'Adulte, Vandoeuvre Les Nancy), J.-F. Lemeuland (Hôpital Charles Nicolle, Rouen), F. Eb (Groupe Hospitalier Nord, Amiens), J.-L. Fauchere (Cité Hospitalière de la Milètrie, Poitiers), J. Akli (Centre Hospitalier Général, Blois), I. Baudinat (Centre Hospitalier, Chalons en Champagne), E. Bichier (Centre Hospitalier, Saumur), H. Biessy (Centre Hospitalier St Louis, La Rochelle), M. Bietrix (Centre Hospitalier Général, Martigues), C. Bouguigny-Saison (Centre Hospitalier, Soissons), P. Brisou (Hôpital des Armées St Anne, Toulon Naval), J. Carre-Cavelier (Centre Hospitalier, Bayeux), P. Chantelat (Centre Hospitalier Paul Morel, Vesoul), C. Chaplain (Centre Hospitalier, Saint-Denis), M. Cheron (Centre Hospitalier, Saint-Germain-en-Laye), M.-F. Danjoux (Centre Hospitalier Intercommunal, Tarbes), F. Delubac (Centre Hospitalier, Annonay), H. Demontclos (Centre Hospitalier, Bourg en Bresse), Y. Rio and J. Didion (Hôpital Notre Dame de Bon Secours, Metz), G. Chambreuil (Centre Hospitalier départemental, La Roche Sur Yon), J. Dublanchet (Centre Hospitalier Intercommunal, Villeneuve Saint Georges), B. Dubourdieu (Centre Hospitalier, Rodez), J.-C. Croix (Centre Hospitalier, Troyes), P. Emerique (Centre Hospitalier, Remiremont), J.-L. Flipo (Centre Hospitalier, Wissembourg), A. Fremaux (Centre Hospitalier Intercommunal, Creteil), M. Gavignet (Centre Hospitalier Jacques Coeur, Bourges), F. Geffroy (Centre Hospitalier Laënnec, Quimper), A. Kazmierczak (Hôpital du Bocage, Dijon), P. Guiet (Centre Hospitalier, Nemours), E. Jaquen (Centre Hospitalier, Sable-sur-Sarthe), P. Plesiat (Hôpital Jean Minjoz, Besancon), E. Laurens (Centre Hospitalier, Cholet), A. Le Coustumier (Centre Hospitalier, Cahors), F. Leturdu (Centre Hospitalier V. Dupouy, Argenteuil), V. Macchi (Centre Hospitalier, Saint-Vallier), C. Malbrunot (Centre Hospitalier, Corbeil Essonnes).

Author information

Authors and Affiliations

  1. Department of Hospital Health, Centre Hospitalier de Versailles, 177 rue de Versailles, 78157, Le Chesnay Cedex, France

    J. W. Decousser, P. Pina, F. Picot & P. Y. Allouch

Authors
  1. J. W. Decousser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Pina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Picot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Y. Allouch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. W. Decousser.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Decousser, J.W., Pina, P., Picot, F. et al. Comparative In Vitro Activity of Faropenem and 11 Other Antimicrobial Agents Against 250 Invasive Streptococcus pneumoniae Isolates from France. Eur J Clin Microbiol Infect Dis 22, 561–565 (2003). https://doi.org/10.1007/s10096-003-0990-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-003-0990-7

Keywords

Search

Navigation